TSHA Company Profile and Key Details

TSHA has shown weak momentum, losing -4.53% over the past week and -1.69% over the past quarter, though year-to-date performance is down -15.64%. Short-term trend indicators are mixed aligned (SMA20 -1.36%, SMA50 -8.22%, SMA200 19.99%). The stock’s 14-day RSI is 45.21 (neutral), while the ATR of 0.27 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -24.09% below its high and over 335.24% above its low. Average 10-day trading volume of 2.35 million shares is below the 3-month average of 3.00 million, indicating normal recent market interest.

Taysha Gene Therapies, Inc. has 287.36 million shares outstanding. The public float is 205.97 million shares, elevated short interest at 16.05% of float. This equals 45.29 million shares. The short ratio is 10.3 days. Institutional investors hold 95.57% of the float. Insiders own 9.63%. Session R.A. II holds 8.87 million shares, Nolan Sean P. has 2.91 million shares and Manning Paul B has 2.84 million shares. Over the past six months, insider transactions show net selling. They sold 401.66 thousand shares across 3 transactions.

Taysha Gene Therapies, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.24. This means the shares are trading above this model’s fair value.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) closed at $5.86 USD, losing -$0.01 (-0.26%) from the previous close of $5.88. The stock is currently mid-range between its 52-week high and low $2.54 and $7.30. With a market capitalization of about $1.87 billion, Taysha Gene Therapies, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.16). Key stats such as the average daily volume over the past year has been around 3.05 million shares, volume is running light vs its 52-week average. Headquartered in Dallas, TX, Taysha Gene Therapies, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sean Nolan, the company employs approximately 99 people and listed since September 24, 2020. Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors.

Taysha Gene Therapies, Inc. generated EPS of -$0.35 over the past year. Five-year average earnings growth is -63.99%. Wall Street analysts project EPS growth of -10.28% annually over the next five years. The latest quarter delivered EPS of -$0.12. The next quarter is forecast at -$0.10. Next year's EPS is expected at $70.05. Analyst sentiment is bullish. Analyst rating data shows there are 9 Strong Buy ratings, 15 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $17.00 to $8.00. The high target offers 190.1% upside. The low target suggests 36.52% downside. The mean target is $11.71. This offers 99.83% upside. Taysha Gene Therapies, Inc. earnings surprise history is a mixed track record. The quarter that ended May 06, 2026, missed forecasts by 20.0%. The prior quarter beat by -27.27%. Over the last six quarters, Apple has recorded several small beats. These include -12.5% in February 26, 2025.

Our AI price prediction model suggests that Taysha Gene Therapies, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.46%, with price expected at $5.13 by August 13, 2026, within a range of $4.81 to $5.47 3-Month Outlook: Projected rise of 35.84%, reaching $7.96 by October 28, 2026, with a range of $7.86 to $8.09. 1-Year Outlook: Projected gain of 328.5%, with price at $25.11 by July 30, 2027, within a range of $25.52 to $25.89.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares are down -15.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Taysha Gene Therapies, Inc. trading at a premium to the broader market with a P/E of -15.24. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.30, suggesting 126.96% upside. Our AI forecast model points to short-term weakness (-12.46% over two weeks), a medium-term rise (35.84% over three months), and a longer-term gain (328.5% over one year), with expected trading ranges indicating moderate volatility.

Taysha Gene Therapies, Inc. trades at a P/E ratio of -15.24, slightly below the S&P 500 average, with a price-to-sales ratio of 249.82 and a price-to-book ratio of 10.09 reflecting a rich premium to book value. The P/FCF stands at -16.18, also below market averages. Compared to sector medians, Taysha Gene Therapies, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.